PRT-1419 is under clinical development by Prelude Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRT-1419’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRT-1419 overview
PRT-1419 is under development for the treatment of solid tumors, sarcoma, melanoma, small cell lung cancer, non-small cell lung cancer, DLBCL, triple negative breast cancer, relapsed and refractory hematologic malignancies including multiple myeloma (MM), t-cell lymphomas, chronic myelomonocytic leukemia (CMML), non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), chronic lymphocytic leukemia, B-cell non-hodgkin lymphoma (NHL) including follicular lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma, myeloproliferative neoplasm overlap syndrome and high-risk myelodysplastic syndrome (MDS). The drug candidate is administered by oral route and intravenous route of administration. It acts by targeting MCL1.
Prelude Therapeutics overview
Prelude Therapeutics (Prelude) is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The company product pipeline includes PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor and PRT3645, a next-generation CDK4/6 inhibitor. Prelude others pipeline includes PRT3789 a first-in-class SMARCA2/BRM protein degraded. It also carries out clinical trials. The company serves throughout the US . Prelude is headquartered in Wilmington, Delaware, the United States.
For a complete picture of PRT-1419’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
